Asset
Muzastotug
Adagene Inc. American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05405595 | phase1_2 | recruiting | 2022-06-15 | 2026-10-31 | Adagene Inc | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.